Abstract
Chronic kidney disease carries a very high mortality risk, in particular from cardiac diseases. Often heart failure and renal failure coincide, a phenomenon referred to as the cardio renal syndrome. In recent years, it has become clear that not only fibrotic repair but also restoration of damaged kidney and heart can occur and the use of cell therapy has been advanced as a means to activate endogenous repair mechanisms or even to re-introduce repairing tissue. In this perspective, mesenchymal stromal cells are of particular interest, since these cells have both immune modulating and reparative functions and are on the brink of entering the clinical arena. Indeed, MSCs can trigger numerous therapeutic biologic processes that contribute to both renal and cardiac repair; however exact mechanisms of actions are largely unknown. In the present review we have made a critical appraisal of the data available with respect to origin and function of MSCs, and we discuss both preclinical as well as clinical evidence on their therapeutic potential in kidney and heart disease.
Keywords: Mesenchymal stromal cells, renal disease, cardiac disease, organogenesis, repair, immune modulation.
Current Pharmaceutical Design
Title:Mesenchymal Stromal Cell Therapy for Cardio Renal Disorders
Volume: 20 Issue: 14
Author(s): Marlies E.J. Reinders, Danielle G. Leuning, Johan W. de Fijter, Martin.J. Hoogduijn and Ton J. Rabelink
Affiliation:
Keywords: Mesenchymal stromal cells, renal disease, cardiac disease, organogenesis, repair, immune modulation.
Abstract: Chronic kidney disease carries a very high mortality risk, in particular from cardiac diseases. Often heart failure and renal failure coincide, a phenomenon referred to as the cardio renal syndrome. In recent years, it has become clear that not only fibrotic repair but also restoration of damaged kidney and heart can occur and the use of cell therapy has been advanced as a means to activate endogenous repair mechanisms or even to re-introduce repairing tissue. In this perspective, mesenchymal stromal cells are of particular interest, since these cells have both immune modulating and reparative functions and are on the brink of entering the clinical arena. Indeed, MSCs can trigger numerous therapeutic biologic processes that contribute to both renal and cardiac repair; however exact mechanisms of actions are largely unknown. In the present review we have made a critical appraisal of the data available with respect to origin and function of MSCs, and we discuss both preclinical as well as clinical evidence on their therapeutic potential in kidney and heart disease.
Export Options
About this article
Cite this article as:
Reinders E.J. Marlies, Leuning G. Danielle, Fijter W. de Johan, Hoogduijn Martin.J. and Rabelink Ton J., Mesenchymal Stromal Cell Therapy for Cardio Renal Disorders, Current Pharmaceutical Design 2014; 20 (14) . https://dx.doi.org/10.2174/13816128113199990477
DOI https://dx.doi.org/10.2174/13816128113199990477 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Triiodothyronine (T3) Effects on Cardiovascular System in Patients with Heart Failure
Recent Patents on Cardiovascular Drug Discovery Gender Differences in the Treatment of Ischemic Heart Disease
Current Pharmaceutical Design Discussion on Pharmacogenetic Interaction in G6PD Deficiency and Methods to Identify Potential Hemolytic Drugs
Cardiovascular & Hematological Disorders-Drug Targets Vitamin D and Cardiovascular Disease: A Novel Agent for Reducing Cardiovascular Risk?
Current Vascular Pharmacology Synthesis and Cytotoxic Activity of 4-Aryl-4H-chromeno[4,3-d] [1,2,3] selenadiazoles
Letters in Drug Design & Discovery Editorial (Thematic Issue: What's Behind the Sex Gap in Cardiovascular Mortality?)
Current Pharmaceutical Design The Rapidly Changing Composition of the Global Street Drug Supply and its Effects on High-risk Groups for COVID-19
Current Psychopharmacology Subject Index To Volume 2
Current Psychiatry Reviews Concepts for Nano-delivery of Therapeutic Immunomodulatory Agents
Current Bionanotechnology (Discontinued) Stem Cell Therapy for Ischaemic Stroke: Translation from Preclinical Studies to Clinical Treatment
CNS & Neurological Disorders - Drug Targets New Pharmacologic Approaches to Prevent Thromboembolism in Patients with Atrial Fibrillation
Current Vascular Pharmacology Micro- and Macrovascular Treatment Targets in Scleroderma Heart Disease
Current Pharmaceutical Design Pathophysiology, Diagnosis and Clinical Management of Hepatorenal Syndrome: From Classic to New Drugs
Current Vascular Pharmacology Application of Resveratrol in Diabetes: Rationale, Strategies and Challenges
Current Molecular Medicine The Challenges in Moving from Ageing to Successful Longevity
Current Vascular Pharmacology Significance of Biotic Factors in Mesenchymal Stem Cell Fate in Regenerative Medicine
Current Stem Cell Research & Therapy Metabolism of Rhaponticin and Activities of its Metabolite, Rhapontigenin: A Review
Current Medicinal Chemistry Radionuclide PET and PET/CT in Coronary Artery Disease
Current Pharmaceutical Design C-Reactive Protein: Interaction with the Vascular Endothelium and Possible Role in Human Atherosclerosis
Current Pharmaceutical Design A Clinical Decision Support System for Assessing the Risk of Cardiovascular Diseases in Diabetic Hemodialysis Patients
Current Diabetes Reviews